ESRRB — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Fulvestrant (SCHEMBL8209)	0.54	8/20
Fulvestrant (SCHEMBL8210)	0.54	8/20
Fulvestrant (SCHEMBL408338)	0.54	8/20
Fulvestrant (SCHEMBL789659)	0.54	8/20
SCHEMBL638890	1.00	7/20
SCHEMBL638891	1.00	7/20
SCHEMBL638915	1.00	7/20
SCHEMBL639036	0.77	7/20
SCHEMBL639037	0.77	7/20
SCHEMBL639038	0.77	7/20
SCHEMBL1289625	0.76	7/20
SCHEMBL1289666	0.62	7/20
Fulvestrant (SCHEMBL1028887)	0.41	7/20
SCHEMBL1289555	0.78	6/20
SCHEMBL1289605	0.68	6/20
SCHEMBL1151837	0.67	6/20
SCHEMBL1151938	0.67	6/20
SCHEMBL1151939	0.67	6/20
SCHEMBL1152003	0.58	6/20
SCHEMBL1152006	0.58	6/20

Clinical trials — most relevant to ESRRB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Chronic Effects of Estrogen in Microcirculation	PHASE4	COMPLETED
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women	PHASE3	COMPLETED
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation	PHASE3	UNKNOWN
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
Phase II Study of Single Agent Lenvatinib	PHASE2	UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer	PHASE2	SUSPENDED
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer	PHASE2	UNKNOWN
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	COMPLETED
S-Equol in Alzheimer's Disease (SEAD) Trial	PHASE1	COMPLETED
Impact of Endogenous E2 on SSI and GH Rebound	PHASE1	COMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
Study of Biomarkers in Tissue Samples From Patients With Breast Cancer	nan	UNKNOWN
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions	nan	UNKNOWN
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH	nan	WITHDRAWN
Sexual Hormones and Haemostasis: Observations for Women Health	nan	UNKNOWN
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation?	nan	UNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients	nan	UNKNOWN
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer	nan	COMPLETED
REFUEL PCOS Study 1	nan	UNKNOWN
Expression of Steroid Receptors in Endometrium	nan	COMPLETED
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes	nan	NOT_YET_RECRUITING
Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Association of Tumour Grade and Sex Steroid Receptor as a Prognostic Index in Breast Cancer	nan	UNKNOWN
Study of Adrenal Gland Tumors	nan	COMPLETED
The Effect of Androgen Receptor Polymorphism on Endometrial Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ESRRB binder may also engage these)

Protein	Name	Similarity
P11475	—	1.000	P11475 →
Q90416	—	1.000	Q90416 →
Q05343	—	0.999	Q05343 →
P62509	—	0.999	P62509 →
F1QLY4	—	0.999	F1QLY4 →
P37234	—	0.999	P37234 →
P62510	—	0.998	P62510 →
Q9QWM1	—	0.998	Q9QWM1 →
Q90417	—	0.998	Q90417 →
P51448	—	0.998	P51448 →
P57797	—	0.998	P57797 →
Q9YGL3	—	0.998	Q9YGL3 →
P49882	—	0.997	P49882 →
P70033	—	0.997	P70033 →
Q5RAM2	—	0.997	Q5RAM2 →
NR5A2	Nuclear receptor subfamily 5 group A member 2	0.997	landscape →
RORA	Nuclear receptor ROR-alpha	0.997	landscape →
Q28037	—	0.997	Q28037 →
Q15406	—	0.996	Q15406 →
HNF4A	Hepatocyte nuclear factor 4-alpha	0.996	landscape →
P35396	—	0.996	P35396 →
P28705	—	0.996	P28705 →
RXRG	Retinoic acid receptor RXR-gamma	0.996	landscape →
Q61539	—	0.996	Q61539 →
Q21878	—	0.996	Q21878 →
P49698	—	0.996	P49698 →
Q18192	—	0.996	Q18192 →
Q9WUU6	—	0.996	Q9WUU6 →
P49883	—	0.996	P49883 →
Q0GFF6	—	0.996	Q0GFF6 →